February 2024 in “Future science OA” Loss of the Y chromosome and UTY gene activity increases cancer risk in men.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia” 96 citations
,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
49 citations
,
June 1998 in “Journal of Endocrinological Investigation” Cyproterone acetate plus ethinyl estradiol is generally more effective in treating hirsutism, but consider side effects and patient characteristics.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
15 citations
,
April 2011 in “Pediatric Nephrology” New treatments for lupus show promise, but more research is needed, especially for children.
March 2022 in “International Journal of Health Sciences” Pentoxifylline helps hair regrowth in rats with hair loss.
25 citations
,
January 2011 in “Annals of Dermatology” Erlotinib can cause hair loss as a side effect.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
January 2008 in “Central South Pharmacy” A reliable method was developed to measure candesartan in human plasma.
April 2010 in “Nature Reviews Urology” 20 citations
,
December 2015 in “Der Urologe” Combining medications is more effective for treating benign prostatic syndrome symptoms.
June 2019 in “Poster presentations” Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.
May 2024 in “Reactions weekly”
November 2024 in “Rheumatology Advances in Practice” Monitor for early signs of azathioprine toxicity and check blood counts regularly.
14 citations
,
June 2014 in “World Journal of Urology” The herbal combination of saw palmetto and stinging nettle reduces nighttime urination in men with urinary issues.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
1 citations
,
September 2001 in “PubMed” Phenytoin, a medication, can cause hair loss and trigger a condition similar to lupus.
97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
40 citations
,
March 2019 in “Pharmaceutical development and technology” Smaller particles of the drug carrier penetrated skin better, with 300 nm size being best for targeting hair follicles.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
6 citations
,
August 2020 in “JCRPE” A boy with a rare form of early puberty caused by a new gene mutation responded well to treatment aimed at reducing testosterone and preserving adult height.
5 citations
,
January 2014 in “Indian Journal of Nephrology” A woman with lupus had muscle weakness due to kidney issues and was successfully treated with medication.
January 2009 in “Chemical Reagents” The method produces finasteride with a 92% yield.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
December 2023 in “Journal of Science Innovations and Nature of Earth” Tribulus terrestris may protect the liver from drug damage.
64 citations
,
March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.